Please login to the form below
antifungal
This page shows the latest antifungal news and features for those working in and with pharma, biotech and healthcare.
Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
antifungal agent Mycamine (micafungin sodium) from Astellas.
Latest news
-
FDA approves Scynexis’ Brexafemme for recurrent vulvovaginal candidiasis
The antifungal is already approved in the US for vulvovaginal candidiasis. ... The decision makes Brexafemme, a novel oral antifungal, the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) – approved in June
-
WHO publishes first-ever fungal priority pathogens list in face of antimicrobial resistance
The FPPL is focused on accelerating further research and policy interventions as a means of reinforcing the global response to fungal infections and antifungal resistance. ... The fungal pathogens of in each category are put in order primarily due to
-
EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin
to $529m in milestone payments, plus royalties, in return for commercial rights to the antifungal drug in all markets outside the US and Japan.
-
COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals
Antifungal-resistant threats also rose in 2020, the report has shown, with a 26% increase in infections in hospitals.
-
Shionogi and F2G partner to develop antifungal treatment olorofim
The deal, worth up to $480m, involves the first novel antifungal treatment developed in the last 20 years. ... Shionogi and F2G have partnered to develop and commercialise the new antifungal agent olorofim – formerly F901318 – for invasive fungal
More from news
Approximately 4 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.
-
Astellas: Ten years young
class of OAB treatments to emerge in over 30 years, the antifungal Mycamine (micafungin) and the anti-infective Dificlir - the first new treatment in 50 years for clostridium difficile or c.
-
Medius Deal Watch table for March 2015
109. Astellas / Vical. Licence and collaboration. Preclinical antifungal ASP2397. 100.
-
Pharma deals during October 2013
This proved to be the case with Dow Pharmaceutical Sciences, which had undertaken development work for Anacor on the topical antifungal tavaborole for the treatment of onychomycosis under a 2004 master
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
AstraZeneca’s John Rex joins UK biotech F2G
We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”. ... In his new role Rex will be tasked with helping move F2G's first-in-class antifungal
-
F2G appoints chief financial officer
Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.
-
Cidara Therapeutics makes senior appointments
Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Action on Anti-microbial resistance: Will the UK rise to the challenge
Antimicrobials include antibiotics as well as antivirals, antifungals and antiparasitics, which all have a vital role in preventing infections in humans, animals and plants. ... England. It will be interesting to see whether the scheme will be rolled out
-
Integrated NHS finances: what do they mean for High Cost Drugs?
However, for some older products, such generic chemotherapy, antifungals and Cytomegalovirus (CMV) drugs, the budget will be devolved to the system single pot.
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
NP339, NovaBiotics’ novel antifungal peptide is anticipated as being phase 1 ready as a candidate for invasive fungal disease by H2 2021 and is now being developed as an inhaled antifungal
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
